文献速递头颈甲状腺与浅表介入US

超声引导热消融治疗甲状腺乳头状癌术后颈部淋巴结复发

Efficacy and Safety of Ultrasound-Guided Thermal Ablation for Locally Recurrent Cervical Lymph Node Metastasis After Thyroidectomy in Papillary Thyroid Carcinoma: A Multicenter Retrospective Study.
PubMed 文献 · Acad Radiol · 2026-09-17

该多中心回顾性研究纳入101例甲状腺乳头状癌术后颈部淋巴结复发患者,共128枚转移淋巴结行超声引导下射频或微波消融。结果显示技术成功率100%,1个月技术有效率97.65%,平均随访29.09个月局部肿瘤进展率8.59%。消融后血清甲状腺球蛋白显著下降,末次随访平均体积缩小率98.86%,主要并发症发生率0.99%,提示对不宜或拒绝再次手术的经选择患者为可选微创局部治疗手段。

要点

  • 1个月CEUS无残留增强判为技术有效,本组有效率为97.65%
  • 消融后Tg显著下降,可从13.02±15.97降至0.12±0.36 ng/mL
  • 主要并发症发生率0.99%,轻微并发症9.9%,总体安全性较好

核心结论

  • 对经选择的PTC术后颈部淋巴结复发患者,超声引导热消融技术成功率高、局部控制较好、病灶明显缩小、主要并发症发生率低
  • 该研究为回顾性单臂设计,无手术或主动监测对照,结果应视为探索性真实世界证据而非确立优于其他处理策略

研究设计与样本

  • 回顾性多中心研究,纳入2018年1月至2025年12月三家三级中心101例患者128枚转移淋巴结
  • 病灶均经细针穿刺细胞学和/或洗脱液甲状腺球蛋白证实,采用射频消融或微波消融
  • 所有病灶须在实时超声上可见且经安全进针路径技术上可及,因再次手术不适合或患者拒绝而选择消融
  • 随访时间点为术后1个月、3个月、6个月、每6个月至2年、此后每年

关键影像表现/征象

  • 术后1个月以对比增强超声无残留增强判为完全消融
  • 末次随访平均体积缩小率为98.86%±5.93%,病灶体积明显缩小

诊断标准与关键数值

  • 技术成功率100%(128/128枚淋巴结)
  • 术后1个月技术有效率97.65%(125/128枚淋巴结)
  • 平均随访29.09±8.05个月(范围6–48个月),局部肿瘤进展率8.59%(11/128枚)
  • 血清Tg由消融前13.02±15.97 ng/mL降至末次随访0.12±0.36 ng/mL(p<0.001)
  • 主要并发症发生率0.99%(1/101例),轻微并发症发生率9.9%(10/101例)

临床应用与阅片要点

  • 消融前需确认转移灶经穿刺细胞学和/或洗脱液Tg证实,并评估实时超声可见性与安全进针路径
  • 术后1个月应行对比增强超声评估有无残留增强,作为技术有效判断依据
  • 随访中应监测血清Tg变化及淋巴结体积缩小情况,并警惕局部肿瘤进展

局限性

  • 回顾性单臂研究,缺乏手术或主动监测对照组,无法确立消融优于其他处理策略
  • 结果来自经高度选择的患者,外推至所有复发性淋巴结转移患者需谨慎

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Post-thyroidectomy recurrent cervical lymph node (LN) metastasis from papillary thyroid carcinoma (PTC) remains a clinical challenge and repeat surgery in a previously operated neck can be technically difficult and morbid. Ultrasound-guided thermal ablation (US-guided TA) has emerged as a minimally invasive treatment option, but contemporary multicenter real-world data with clearly defined short-term and longitudinal outcomes remain limited. This study evaluated the efficacy and safety of US-guided TA for treating locally recurrent cervical LN metastases from PTC in a multicenter cohort.

MATERIALS AND METHODS: This retrospective multicenter study included 101 patients with 128 metastatic LNs treated at three tertiary centers between January 2018 and December 2025. Eligible lesions were confirmed by fine-needle aspiration biopsy cytology and/or washout thyroglobulin and were treated with radiofrequency ablation (RFA) or microwave ablation (MWA) because repeat surgery was considered unsuitable or was declined by the patient. All lesions had to be visible on real-time ultrasonography and technically accessible through a safe needle route. Follow-up was performed at 1 month, 3 months, 6 months, every 6 months until 2 years, and annually thereafter. Primary outcomes included technical success, technique efficacy at 1 month (complete ablation without residual enhancement on contrast-enhanced ultrasound), local tumor progression (LTP), and complication rates. Secondary outcomes were serum thyroglobulin (Tg) change and volume reduction ratio (VRR). Exploratory regression analyses were performed to assess factors associated with LTP.

RESULTS: Technical success was achieved in 100% of treated LNs. The technique efficacy rate at 1 month was 97.65% (125/128 LNs). During a mean follow-up of 29.09± 8.05months (range, 6-48months), the LTP rate was 8.59% (11/128 LNs). Major complications occurred in 0.99% of patients (1/101), and minor complications occurred in 9.9% (10/101). Serum Tg levels decreased significantly from 13.02 ± 15.97 ng/mL before ablation to 0.12 ± 0.36ng/mL at the last follow-up (p < 0.001). The mean VRR at the last follow-up was 98.86%±5.93%.

CONCLUSION: In this selected multicenter cohort, US-guided TA was associated with high technical success, favorable local control, marked lesion shrinkage, and low major-complication rate for locally recurrent cervical LN metastases from PTC. Because this was a retrospective single-arm study without a surgical or surveillance comparator, these findings should be regarded as exploratory real-world evidence supporting TA as a possible minimally invasive locoregional treatment option for carefully selected patients who are unsuitable for or decline repeat surgery, rather than establishing superiority to alternative management strategies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Wu, Li, et al. Efficacy and Safety of Ultrasound-Guided Thermal Ablation for Locally Recurrent Cervical Lymph Node Metastasis After Thyroidectomy in Papillary Thyroid Carcinoma: A Multicenter Retrospective Study. Acad Radiol. 2026. PMID: 42754433. doi:10.1016/j.acra.2026.08.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。